(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(-0.07%) $80.00
(0.46%) $2.64
(0.10%) $2 419.80
(1.65%) $31.78
(0.43%) $1 094.70
(-0.10%) $0.919
(-0.18%) $10.68
(-0.22%) $0.787
(0.19%) $91.05
@ $4.00
发出时间: 14 Feb 2024 @ 04:29
回报率: -7.00%
Live Chart Being Loaded With Signals
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections...
Stats | |
---|---|
今日成交量 | 7 046.00 |
平均成交量 | 42 814.00 |
市值 | 19.40M |
EPS | $0 ( 2023-12-18 ) |
下一个收益日期 | ( $-0.550 ) 2024-05-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.460 |
ATR14 | $0.0340 (0.91%) |
Evaxion Biotech A/S 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Evaxion Biotech A/S 财务报表
Annual | 2023 |
营收: | $73 112.00 |
毛利润: | $73 112.00 (100.00 %) |
EPS: | $-8.11 |
FY | 2023 |
营收: | $73 112.00 |
毛利润: | $73 112.00 (100.00 %) |
EPS: | $-8.11 |
FY | 2022 |
营收: | $0 |
毛利润: | $-571 319 (0.00 %) |
EPS: | $-9.80 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.514 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。